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Comparison of a Treatment Strategy Combining
CCI-779 Plus DTIC Versus DTIC Monotreatment
in Human Melanoma in SCID Mice
Christiane Thallinger1,2, Johannes Werzowa3, Wolfgang Poeppl1, Florian M. Kovar1, Barbara Pratscher3,
Peter Valent2, Peter Quehenberger4 and Christian Joukhadar1,2,5
This study compares the antineoplastic potential of a novel treatment strategy combining cell cycle inhibitor-779
(CCI-779) plus dacarbazine (DTIC) versus DTIC monotreatment, the current chemotherapeutic mainstay in
combating metastatic melanoma. A controlled four-group parallel study design comprising 24–40 mice per
tumor cell line was used in a severe combined immunodeficiency (SCID)-mouse xenotransplantation model.
SCID mice were injected with 518A2, Mel-JUSO, or 607B human melanoma cells. After they developed tumors,
mice received daily CCI-779 or solvent over 14 days. From treatment day 4–8 mice were additionally injected with
DTIC or saline. Treatment with CCI-779 plus DTIC was superior to single agent DTIC in two out of three cell lines
(Po0.05). The tumor weight reduction was 44717 and 6176% compared with DTIC monotreatment in Mel-
JUSO and 607B melanomas, respectively (Po0.05). In contrast, in 518A2 xenotransplants, CCI-779 plus DTIC
treatment was as effective as DTIC monotreatment. CCI-779 monotherapy exerted no statistically significant
antitumor effect. Collectively, these data indicate that CCI-779 has the potential to increase the chemother-
apeutic efficacy, as the combination of CCI-779 plus DTIC proved to be more efficacious compared to DTIC
monotherapy in two out of three melanoma cell lines in vivo.
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INTRODUCTION
Because of its effect on growth arrest, apoptosis, and
angiogenesis, rapamycin, an approved immunosuppressive
agent, is currently under investigation as a potential anti-
cancer drug (Geoerger et al., 2001; Frost et al., 2004). An
ester analogue of rapamycin is the cell-cycle inhibitor-779
(CCI-779). CCI-779 interacts with the mammalian target of
rapamycin called mTOR (Gallicchio et al., 2003), which is a
downstream effector of the phosphatidylinositol 3-kinase
(PI3K)/acutely transforming retrovirus AKT8 in rodent T cell
lymphoma (Akt) signaling pathway. mTOR regulates in
response to growth factors, hormones (Schmelzle and Hall,
2000; Gingras et al., 2001a), mutagens and amino acids
(Abraham and Wiederrecht, 1996; Schmelzle and Hall, 2000;
Gingras et al., 2001b), protein translation, cell-cycle progres-
sion, and cellular proliferation. However, the intensity of
mTOR is not exclusively decisive for the antineoplastic effect
of CCI-779. It has become clear over the past years that the
loss of phosphatase and tensin homolog deleted on chromo-
some ten (PTEN) and subsequent activation of Akt are critical
events in tumorigenesis.
Recent in vitro investigations have demonstrated that CCI-
779 inhibits cell growth as well as restores sensitivity to
apoptosis induced by chemotherapeutic agents, but despite
encouraging data, current preclinical and clinical investiga-
tions have focused mainly on the antineoplastic effects of
CCI-779 in monotherapeutic use (Shi et al., 1995; Seufferlein
and Rozengurt, 1996; Woltman et al., 2003; Panwalkar et al.,
2004; Stromberg et al., 2004; Wu et al., 2005).
To date, the alkylating agent dacarbazine (DTIC)
represents a chemotherapeutic cornerstone in the treatment
of metastatic melanoma (Li and McClay, 2002). The response
rates are discouraging with values of not more than 25%
in human melanoma. Against this background, this study
was carried out to evaluate and compare the effect of
the antineoplastic agent CCI-779 in combination with DTIC
versus DTIC monotreatment in three different melanoma
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ned immunodeficiency (SCID)-mouse xenotransplantation
model.
RESULTS
mTOR, p-mTOR, PTEN, p-Akt, and p-S6K1 expression of
melanoma in vitro and in vivo
The three human melanoma cell lines 518A2, Mel-JUSO, and
607B expressed mTOR, the target structure of CCI-779 in
vitro and in vivo (Figures 1 and 5). The activity of mTOR is
influenced by its phosphorylation state, which was almost the
same in all three cell lines (Figures 1 and 5). PTEN loss and
subsequent activation of Akt are critical events in tumorigen-
esis. PTEN as well as Akt were expressed in all three cell lines
in vitro and in vivo. Western blot analysis showed that the
expression of PTEN was strongest in 607B melanomas when
compared to 518A2 or Mel-JUSO cells. Surprisingly, treat-
ment with CCI-779 increased the protein level of p-Akt, an
effect which may be explained by feedback regulation in
vitro and in vivo (Figures 1 and 5). We also analyzed the
expression of p-S6K1, a kinase, which is regulated by mTOR
and regulates cell growth itself. As presented in Figure 1b, a
moderate decrease of p-S6K1 was observed after treatment
with CCI-779. Analyzing tumor xenografts for p70 S6K
expression showed a significant cytoplasmic p70 S6K
decrease after CCI-779 treatment, whereas the nuclear
expression pattern remained nearly unaffected (Figure 4,
Supplementary Figure S1). These in vitro and in vivo data can
be interpreted to mean that CCI-779 treatment is effective in
mTOR inhibition.
Growth inhibition of human melanoma xenotransplants in SCID
mice
After 2 weeks of therapy with study drugs, mice were killed
and tumor weight was evaluated (Figure 2, Table 1). The
combinatorial treatment regimen with CCI-779 plus DTIC
was superior to single agent DTIC in two out of three cell
lines tested (Po0.05). The tumor weight reduction was
44717 (Po0.05) and 6176% (Po0.05) compared to DTIC
monotreatment in Mel-JUSO and 607B melanomas, respec-
tively. In contrast, in 518A2 xenotransplants CCI-779 plus
DTIC treatment was as effective as DTIC monotreatment
(P40.05) and reduced the tumor weight by 8577%
compared to saline (Po0.05). The combinatorial treatment
regimen with CCI-779 plus DTIC resulted in a statistically
significant tumor weight reduction in all three cell lines
compared to solvent control and CCI-779 monotreatment
(Po0.05) (Figure 2, Table 1). CCI-779 monotherapy exerted
no statistically significant antitumor effect compared to DTIC
monotreatment in any cell line evaluated (P40.05). These
data were confirmed by measurements of tumor volumes by
the use of the caliper method twice weekly during the course
of the experiment (Figure 2, left panel; Table 1).
Side effects
Mice treated with CCI-779 plus DTIC displayed the lowest
body weights in all three cell lines. In this therapy group,
body weight reduction reached only the level of statistical
significance in mice bearing Mel-JUSO melanomas com-
pared to solvent control (Po0.05). Animals treated solely
with CCI-779 showed no significant reduction of mean body
weight when compared to mice treated with solvent control
or DTIC only (P40.05, Table 1).
In mice treated with either DTIC only or with a
combination of CCI-779 plus DTIC, we observed side effects
such as piloerection and ruffled fur. No histological signs of
toxicity were evaluated by cross-pathological examination of
the liver, lung, and intestine in the animals. Diarrhea was not
observed in the mice.
Apoptosis in melanoma xenografts
To assess whether the observed antitumor effects of the
combinatorial treatment regimen with CCI-779 plus DTIC
were associated with an increase of apoptotic cells,
melanoma xenografts were examined by TUNEL staining
(Figure 3). CCI-779 plus DTIC generated the highest number
of apoptotic cells when compared to all other treatment
regimens.
Regarding DTIC monotherapy, in 607B xenografts, DTIC
monotherapy failed to induce apoptosis. In contrast, in
518A2 melanomas DTIC, monotreatment exerted almost
the same increase of apoptotic cells compared to xenografts
treated with a combination of CCI-779 plus DTIC. This might
explain the almost comparable reduction of tumor weights
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Figure 1. Expression of mTOR, Akt, PTEN, and S6K1 in human melanoma
cells. (a) Relevant key parts of the mTOR/Akt pathway were evaluated by
Western blot (10% polyacrylamide gel). The target structure of CCI-779,
namely p-mTOR, was expressed in all three melanoma cell lines. PTEN, a
tumor suppressor, was most weakly expressed in Mel-JUSO and strongest in
607B human melanoma cell lines. (b) Treatment of human melanoma cells
with CCI-779 increased the expression of p-Akt, when compared to untreated
controls in all three melanoma cell lines evaluated. In contrast, protein
expression of p-S6K1 decreased when treated with CCI-779. Each lane was
loaded with 10 mg protein. Representative blots of different gels are shown.
(c) Quantification of Western blot bands by densitometry. Data are presented
as a percentage of controls (actin).
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seen in CCI-779 plus DTIC and DTIC monotreatment of
518A2-xenotransplants.
DISCUSSION
mTOR inhibitor CCI-779 appears to be a compelling novel
anticancer candidate because of its limited toxicity and
potential additive cytotoxicity if combined with other
cytotoxic agents. Thus, this work was carried out to compare
the antineoplastic effect of a promising treatment strategy,
combining CCI-779 plus DTIC versus DTIC monotreatment in
three different human melanoma cell lines using a SCID-
mouse xenotransplantation model.
The main finding of our investigation was that the
antineoplastic effect of CCI-779 plus DTIC was significantly
superior to single agent treatment with DTIC in Mel-JUSO
and 607B melanomas, but failed to be superior in 518A2
melanomas (Figure 2, Table 1). In 518A2 xenotransplants,
CCI-779 plus DTIC treatment was as effective as DTIC
monotreatment (P40.05).
In the SCID-mouse model used, the observed response
rates to DTIC monotreatment are in excellent accordance
with data reported previously in humans (Huncharek
et al., 2001; Li and McClay, 2002). As expected from
previous animal data and clinical investigations, the anti-
neoplastic effect of DTIC monotreatment showed high
interindividual variability ranging from 8577% growth
inhibition in 518A2 melanomas to undetectable antitumor
effects in 607B tumors compared to solvent control (Figure 2,
Table 1).
CCI-779 monotherapy exerted a moderate but statistically
nonsignificant growth-inhibitory effect on all cell lines in vivo
(P40.05) (Figure 2). These data are in line with a recently
published phase II trial showing that CCI-779 is not
sufficiently active in melanoma to warrant further testing as
a single agent (Margolin et al., 2005).
To make the point about the observed antineoplastic
effects of CCI-779, we analyzed important key regulators
along the PI3K/Akt pathway.
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Figure 2. Effect of CCI-779 treatment on melanoma growth in SCID mice. Depending on the cell lines used, the overall observation period varied from 23 to 34
days. SCID mice with 518A2, Mel-JUSO, or 607B melanomas received a 14-day treatment (day 1–14) with CCI-779 (1.5 mg/kg intraperitoneally) or solvent
control (6–10 animals per group). In addition, animals received 80 mg/kg of DTIC intraperitoneally on treatment days 4–8. At the end of the experiment, mice
were killed and tumors were resected and weighed (right panel). Tumor weight is provided in grams. During the course of the experiment, tumor size was
assessed by caliper measurements (left panel) twice weekly and is shown in mm3 (mean7SD; ¼ statistically significant, Po0.05; n.s.¼ not significant, P40.05).
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mTOR, the target structure of CCI-779, was expressed in all
three melanoma cell lines. As the activity of mTOR is
influenced by its phosphorylation state, we investigated
p-mTOR and detected the strongest expression in Mel-JUSO
and the weakest expression in 518A2 melanoma cells
(Figure 1). However, the level of mTOR and p-mTOR protein
expression did not appear to be exclusively decisive for the
overall antineoplastic effect of CCI-779. It has been shown
previously that altered Akt activity regulates sensitivity to CCI-
779 in prostate and glioblastoma cells in vitro and
in vivo. Thus, high Akt expression renders tumor cells resistant
to CCI-779 treatment (Neshat et al., 2001). Treatment with
CCI-779 increased the p-Akt protein level in all melanoma
cell lines used in vitro and in vivo (Figures 1 and 5). This CCI-
779 effect on the PI3K/Akt axis may be caused by a feedback
activation when mTOR activity is inhibited, a finding that
should be kept in mind when initiating CCI-779 treatment, as
CCI-779 in turn can render tumor cells themselves resistant to
CCI-779 therapy via activation of Akt (Patterson et al., 2006).
Another hint of sufficient mTOR inhibition by CCI-779 is
the detection of the p-S6K1 decrease after CCI-779 treatment
(Figures 1 and 5). The p-S6K1 decrease was moderate in all
Mel-JUSO
DTIC
CCI-779+DTIC
607B 518A2
Figure 3. Treatment with CCI-779 plus DTIC facilitates apoptosis in vivo. Melanoma xenografts treated with either the combination of CCI-779 plus
DTIC or DTIC solely were analyzed by TUNEL assay for apoptotic cell death. TUNEL-positive cells (green) increased in tumors treated with CCI-779 plus
DTIC in Mel-JUSO and 607B xenografts compared to DTIC monotreatment. (Bar¼ 0.1 mm.) Representative photographs of tumor sections are shown.
Table 1. Effects of different treatment regimens on melanoma growth in vivo
Treatment regimen Tumor weight (g) Tumor volume (mm3) Body weight (g)
Mel-JUSO CCI-779+DTIC (n=10) 0.08 (0.02, 0.12) 171.5 (62.5, 269.5) 14.6 (11.31, 15.46)
CCI-779 (n=10) 0.22 (0.13, 0.27) 318.5 (220.5, 600.0) 16.4 (15.05, 19.40)
DTIC (n=9) 0.17 (0.10, 0.28) 320.0 (245.0, 550.0) 15.8 (113.56, 17.71)
Solvent (n=9) 0.35 (0.14, 0.55) 526.5 (294.0, 1,183.0) 17.7 (15.30, 18.99)
518A2 CCI-779+DTIC (n=10) 0.21 (0.01, 0.31) 196.0 (48.0, 416.0) 15.6 (13.52, 16.94)
CCI-779 (n=10) 1.04 (0.44, 1.40) 563.0 (364.5, 1,183.0) 18.3 (14.06, 21.50)
DTIC (n=10) 0.20 (0.01, 0.40) 196.0 (87.5, 600.0) 17.3 (15.35, 18.86)
Solvent (n=10) 1.35 (0.67, 2.01) 1,275.5 (700.0, 1,912.5) 17.9 (12.42, 20.77)
607B CCI-779+DTIC (n=6) 1.04 (0.70, 1.12) 756.3 (320.0, 1,267.5) 17.8 (16.83, 19.25)
CCI-779 (n=6) 1.83 (1.34, 2.48) 1,912.5 (1,089.0, 2,432.0) 20.9 (10.53, 21.62)
DTIC (n=6) 1.95 (1.82, 3.71) 2,538.0 (1,800.0, 3,240.0) 18.8 (17.64, 20.18)
Solvent (n=6) 1.95 (1.17, 3.55) 2,770.8 (1,089.0, 3,564.0) 19.7 (16.63, 20.55)
Summary of the effects of the different treatment regimens on mouse body weight, tumor weight, and tumor volume of Mel-JUSO, 518A2, and 607B human
melanoma xenotransplants after 14 days of therapy in SCID mice. CCI-779 (1.5 mg/kg intraperitoneally) was administered daily, DTIC (80 mg/kg
intraperitoneally) or solvent were injected from day 4 to 8. Data are presented as median (minimum and maximum).
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cell lines. These in vitro data were confirmed by in vivo data.
Immunohistochemical and western blot analysis of tumor
xenografts also showed an impressive decrease of cytoplas-
mic p70 S6K after CCI-779 treatment (Figures 4 and 5).
However, the mechanisms by which mTOR activates its
effector S6K1 are not fully understood. From current knowl-
edge, mTOR either directly stimulates S6K1 via phosphoryla-
tion or indirectly by activating another protein kinase or also
by inhibiting a phosphatase (e.g., protein phosphatase 2A)
(Deldicque et al., 2005). In summary, the observed p-Akt
increase as well as the moderate p-S6K1 decrease after CCI-
779 treatment proved sufficient mTOR inhibition by CCI-779
in our melanoma cells.
Apart from p-Akt and p-S6K1, which are known corner-
stones in the PI3K/Akt pathway, one should similarly pay
attention to the tumor-suppressor PTEN. It has recently
become clear that loss of PTEN is a critical event in
tumorigenesis. In human melanoma PTEN, mutations have
been detected in 30–50% of melanoma cell lines and in
5–20% of uncultured melanomas (Guldberg et al., 1997;
Teng et al., 1997; Tsao et al., 1998; Wu et al., 2005). In our
experiment, PTEN expression was similarly positive in Mel-
JUSO and 518A2 cells. However, the strongest PTEN
expression was observed in the most chemoresistant cell line
(607B cells) (Figures 1 and 2).
The assessment of key regulators, such as Akt, S6K1, and
PTEN in the PI3K/Akt pathway could only partially explain
the observed antineoplastic effects in this study. We, there-
fore, finally set out and visualized tumor growth inhibition by
quantification of apoptosis and cell proliferation. A large
body of literature describes how rapamycin and CCI-779 are
able to increase the sensitivity to apoptosis induced by
chemotherapeutic agents (Shi et al., 1995; Wan and Helman,
2002). The analysis of the melanoma xenografts for apoptotic
cell death by TUNEL assay demonstrated an increase of
apoptotic cells in all melanoma xenografts treated with the
combinatorial treatment regimen compared to DTIC mono-
therapy in Mel-JUSO and 607B melanomas, respectively
(Figure 3). In 518A2 xenotransplants, the increase of
apoptotic cells was almost the same as tumors treated with
the combinatorial treatment regimen or DTIC monotreat-
ment.
Beside apoptosis, mTOR inhibitors also exert antiproli-
ferative effects by inducing an arrest in the G1 phase of the
cell cycle. Therefore, we also examined, in a separate study,
cell proliferation in different melanoma cell lines using the
nuclear antigen Ki-67, a common marker of cell proliferation.
CCI-779 monotreatment generated no relevant inhibition of
cell proliferation independent of the cell line used in the
xenotransplantation model (Thallinger et al., 2007).
It is increasingly clear that combinatorial anticancer
treatment strategies possess the advantage of synergistic
antineoplastic efficacy. In this context, Fan et al. (2006)
518A2 Mel-JUSO
CCI-779 Solvent Solvent SolventCCI-779 CCI-779
607B
Figure 4. Expression of p70 S6K before and after treatment with CCI-779 in vivo. Melanoma xenografts treated with either CCI-779 or solvent control
were analyzed by immunohistochemistry for cytoplasmic and nuclear p70 S6K protein expression. Cytoplasmic p70 S6K expression impressively decreased after
CCI-779 treatment, whereas the nuclear expression pattern remained nearly unaffected. (Bar¼ 0.1 mm upper panel; bar¼ 0.015 mm lower panel.)
Representative photographs of tumor sections are shown.
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Figure 5. Expression of mTOR, Akt, PTEN, and S6K1 in human melanomas
grown in SCID mice. p-mTOR and PTEN protein expression of human
melanomas grown in SCID mice were not influenced by the treatment with
CCI-779. In contrast, treatment of human melanomas with CCI-779 increased
the expression of p-Akt when compared to untreated controls and induced
additionally a slight decrease of p-S6K1 protein expression (15 mg protein
were loaded per lane). Representative blots of different gels are shown.
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recently described a dual PI3K/mTOR inhibitor that revealed
emergent efficacy in glioma. It has been shown that blockade
of the class 1 PI3K impacts only one of two inputs driving
activation of mTOR. Combining a class 1 PI3K inhibitor with
an mTOR inhibitor effectively blocks two separate inputs
promoting activation of mTOR, while also preventing the
activation of class 1 PI3K observed in response to mono-
therapy with mTOR inhibitors. Thus, looking at the literature
and at our study, one can state that mTOR inhibitors might be
potent and valuable partners in combinatorial treatment
settings.
In summary, this paper presents experimental data that
may point to a new drug combination to treat melanoma. We
conclude that the combined treatment with CCI-779 plus
DTIC effectively inhibits human melanoma growth in SCID
mice as the new treatment regimen was superior to single-
agent treatment with DTIC in Mel-JUSO and 607B and was as
effective as DTIC in 518A2 melanomas. However, these data
need to be verified in subsequent preclinical settings before
final conclusions on the value of CCI-779 in the therapy of
melanoma can be drawn.
MATERIALS AND METHODS
Cell lines and culture
The human melanoma cell lines 518A2 and 607B were gifts from P.
Schrier (University of Leiden, The Netherlands). Both cell lines were
derived from melanoma metastases. The cell line Mel-JUSO, which
was originally derived from primary melanoma, was kindly provided
by Dr. J. Johnson (University of Munich, Germany). The cell lines
were maintained in DMEM supplemented with 10% fetal bovine
serum (Gibco, Paisley, UK) and an antibiotic mixture containing
100 U/ml of penicillin, 100 mg/ml of streptomycin, and 0.25 mg/ml
of amphotericin B (all from Gibco) in a fully humidified 5% CO2,
95% ambient air atmosphere at 371C.
Western blot analysis
Cell or tumor extracts were prepared in lyses buffer containing
0.14 M physiologic saline solution, 0.4 M triethanolamine, 0.2% Na-
deoxycholate, and 0.5% Nonidet P-40, supplemented with 1 mM
phenylmethylsulfonyl fluoride, 4.0mg/ml aprotinin, and 4.0 mg/ml
leupeptin. To evaluate p-Akt and p-S6K1 protein expression before
and after CCI-779 treatment, cells were incubated with either CCI-
779 (25 nM) or DMSO vehicle for 24 hours. The amount of soluble
protein was quantified by means of modified Bradford analysis (Bio-
Rad, Richmond, CA). Total lysates (10 mg per lane) were separated by
SDS–polyacrylamide gel electrophoresis and blotted on polyvinyli-
dene fluoride membranes (Millipore, Bedford, MA) and probed with
different antibodies (Cell Signaling Technology, Danvers, MA).
Reactive bands were visualized by a chemoluminescence method.
Protein expression levels were quantified by densitometry of
autoradiograms with an ultrascan XL densitometer (Pharmacia,
Uppsala, Sweden).
In vivo experiments
The study protocol was approved by the Medical University of
Vienna Animal Welfare Committee. All animal studies were
performed according to the Austrian laws and guidelines for animal
care and protection.
Three cell lines were tested in this study (607B, Mel-JUSO, and
518A2). Per cell line, 24–40 female CB-17 scid/scid (SCID) mice (3–4
weeks; Harlan Winkelmann, Borchen, Germany) were randomly
assigned to four experimental groups of six to 10 animals each
(Table 1). SCID mice were injected subcutaneously with 518A2,
Mel-JUSO, or 607B cells (5 106) into the lower left flank.
Study drug administration was initiated (day 1) when animals
developed melanoma nodules of about 5 mm in diameter. CCI-779
solution (Wyeth Pharma, Muenster, Germany) was prepared as
described previously (Geoerger et al., 2001) and was administered
intraperitoneally at a dose of 1.5 mg/kg daily over a period of 14
days. The dose chosen in this study was based on previous
experiments in SCID mice (Koehl et al., 2004) and is in agreement
with those used in humans (Raymond et al., 2004). DTIC (80 mg/kg
intraperitoneally) and solvent control were administered over a
period of 5 days (day 4–8) (Jansen et al., 1998). During the
experiments, tumor volumes were assessed twice weekly by caliper
measurements (Boehm et al., 1997). On treatment day, 14 all
animals were killed.
Apoptosis assays (TUNEL) and immunohistochemistry
The histochemical detection of analysis of apoptosis was performed
by TUNEL assay using fluorescein–deoxyuridine triphosphate (Boeh-
ringer Mannheim, Mannheim, Germany). Tissue sections were
counterstained using 40,6-diamidine-20-phenylindole dihydrochlor-
ide (Roche Diagnostics, Basel, Switzerland). The expression of p70
S6K in vivo was evaluated by immunohistochemistry with an anti-
p70 S6K antibody (Cell Signaling Technology) and a DAKO LSAB 2
system.
Statistical analysis
Statistical significance of differences in tumor weights among
treatment groups was analyzed using Wilcoxon’s tests, Bonferroni’s
adjustments, and Kruskal–Wallis analysis of variance (Statistica 5.1,
Tulsa, OK). A two-sided P-value of less than 0.05 was considered to
be statistically significant.
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